Author: Laura Riva; Shuofeng Yuan; Xin Yin; Laura Martin-Sancho; Naoko Matsunaga; Sebastian Burgstaller-Muehlbacher; Lars Pache; Paul P. De Jesus; Mitchell V. Hull; Max Chang; Jasper Fuk-Woo Chan; Jianli Cao; Vincent Kwok-Man Poon; Kristina Herbert; Tu-Trinh Nguyen; Yuan Pu; Courtney Nguyen; Andrey Rubanov; Luis Martinez-Sobrido; Wen-Chun Liu; Lisa Miorin; Kris M. White; Jeffrey R. Johnson; Christopher Benner; Ren Sun; Peter G. Schultz; Andrew Su; Adolfo Garcia-Sastre; Arnab K. Chatterjee; Kwok-Yung Yuen; Sumit K. Chanda
Title: A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals Document date: 2020_4_17
ID: 1fgnfh62_45
Snippet: Large-scale surveys of existing drugs that may harbor antiviral activities can significantly facilitate such repositioning efforts. A recently reported SARS-CoV-2human protein-protein interaction (PPI) analysis identified 332 viral-host interactions, 66 of which are potential druggable human host factors targeted by 69 known drugs that have FDA approval, however activities on SARS-CoV-2 replication have not yet been reported 63 . An additional st.....
Document: Large-scale surveys of existing drugs that may harbor antiviral activities can significantly facilitate such repositioning efforts. A recently reported SARS-CoV-2human protein-protein interaction (PPI) analysis identified 332 viral-host interactions, 66 of which are potential druggable human host factors targeted by 69 known drugs that have FDA approval, however activities on SARS-CoV-2 replication have not yet been reported 63 . An additional study that tested a focused panel of 48 FDA-approved drugs, previously shown to have antiviral activity against both SARS-CoV and MERS-CoV, author/funder. All rights reserved. No reuse allowed without permission.
Search related documents:
Co phrase search for related documents- additional study and large scale: 1, 2, 3, 4, 5, 6, 7
- additional study and protein protein: 1, 2, 3, 4
- additional study and SARS replication: 1, 2, 3, 4, 5, 6
- additional study and SARS replication activity: 1
- additional study and viral host: 1, 2, 3, 4, 5, 6, 7, 8
- antiviral activity and exist drug: 1, 2
- antiviral activity and FDA approval: 1, 2
- antiviral activity and human host: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- antiviral activity and large scale: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- antiviral activity and protein protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- antiviral activity and SARS protein protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- antiviral activity and SARS replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- antiviral activity and SARS replication activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- antiviral activity and viral host: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- antiviral activity and viral host interaction: 1, 2, 3, 4, 5, 6, 7
- exist drug and SARS replication: 1
- FDA approval and large scale: 1, 2, 3, 4
- FDA approval and protein protein: 1, 2
- FDA approval and SARS protein protein: 1
Co phrase search for related documents, hyperlinks ordered by date